导读： 21 款在研产品储备技术力量！新芝生物 2024 财报透露出什么信号？ 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 4月2 1日，新芝生物发布2 0 2 4年年报。报告显示，公司2 0 2 4年营业收入为1 . 6 8亿元，同比下降11 . 9 0%；归母净利润为4 1 6 2 . 7 7万元，同比下降 2 8 . 4 8%；扣非归母净利润为2 8 2 6 . 4 8万元，同比下降3 2 . 7 8%；基本每股收益0 . 4 7元。 报告期内，新芝生物基本每股收益为0 . 4 7元，加权平均净资产收益率为7 . 7 8%。 以4月2 1日收盘价计算，新芝生物目前市盈率（TTM）约为3 2 . 8 0倍，市净率（LF）约为2 . 6 8倍，市销率（TTM）约为8 . 2 7倍。 根据年报，新芝生物第四季度实现营业总收入5 9 3 9 . 3 5万元，同比下降0 . 2 0%，环比增长4 2 . 0 1%；归母净利润1 9 9 7 . 4 6万元，同比下降3 . 8 0%， 环比增长1 3 2 . 4 7%；扣非净利润2 5 ...

商报讯(记者孟佳俊通讯员姜慧君)4月15日，第137届中国进出口商品交易会(广交会)拉开帷幕，共分三 期举办，首期以"先进制造"为主题。作为产业大区，钱塘(新)区共有中策橡胶集团股份有限公司、逻腾 (杭州)科技有限公司、杭州乐秀电子科技有限公司等42家企业亮相广交会，展位数量达80个，增幅高达 17.6%，创下历史新高。 广交会首日，逻腾(杭州)科技有限公司展位迅速成为焦点。他们带来科技感满满的球形机器人，吸引了 众多观众的目光。逻腾球形机器人实力非凡，具备两栖作业能力，先后参与了公安特警、应急救援、一 线部队组织的多次实战演习。企业相关负责人表示，展会首日就迎来了"开门红"，一天内累计接待了来 自中东、北美等国家和地区的200多位客户，预计这次参展能新增营收超过500万元。 除了机器人，首期钱塘参展企业还涉及橡胶制品、无人机、智能家居等多个领域，且都取得了不俗表 现。在杭州启飞智能有限公司的展位前热闹非凡，其业务经理徐汉伟表示，第一批企业名片与书册在第 一天就发放完毕，他们紧急加印了第二批。"这两天，众多来自东南亚、欧洲等地的客户对我们的无人 机产品表现出浓厚兴趣。" 启飞智能是一家出口占比超过70%的企业 ...

Summary of Conference Call on Chemical Industry Impact by DXX Industry Overview - The discussion centers around the impact of DXX on the chemical industry, emphasizing the integration of AI and intelligent systems as a driving force for development in manufacturing sectors [1][2][3]. Key Points and Arguments 1. **AI Integration and Efficiency**: DXX is expected to significantly enhance the use and efficiency of AI in the chemical industry, acting as a catalyst for improvements in manufacturing processes [1]. 2. **Emerging Trends**: There is a recognition of a latent transformation occurring within the industry, which is gradually gaining attention as low-cost, high-efficiency tools become more prevalent [1]. 3. **Structural Changes in Manufacturing**: The introduction of AI is anticipated to alter the prioritization of various manufacturing factors, such as labor and technology, leading to a structural shift in the industry [3]. 4. **Domestic vs. International Disparities**: The call highlights the differences in manufacturing development between domestic and international players, with domestic firms having a historical advantage in capital-intensive investments [4][5]. 5. **Impact on R&D**: AI is expected to reduce the time and cost associated with new product development, particularly benefiting sectors that require rapid innovation [6][12]. 6. **Capital Investment Characteristics**: The chemical industry is characterized by high capital investment, which influences the overall investment strategy and operational efficiency of firms [7]. 7. **Technological Upgrades**: The industry has undergone significant upgrades post-2017 and 2018, particularly in response to environmental regulations, leading to enhanced digitalization and automation [10]. 8. **Market Adaptation**: Companies are encouraged to adapt to market demands through flexible production and integrated service offerings, which can enhance competitiveness [14]. 9. **Long-term Development Phases**: The discussion outlines two decades of development in the industry, transitioning from a technology-dependent model to a more integrated and market-oriented approach [17][19]. 10. **AI's Role in Cost Management**: AI tools are seen as essential for improving cost management and operational efficiency across the industry [18]. 11. **Future Research Directions**: There is a call for further research into foundational studies that can support future product development and innovation within the industry [14][20]. Additional Important Insights - The integration of AI is not just a technological upgrade but a fundamental shift in how companies operate, with implications for supply chain management and product differentiation [12][21]. - The potential for consolidation among smaller firms in the industry is noted, as they may need to adapt to survive in a more competitive landscape driven by technological advancements [21]. - The call concludes with an emphasis on the importance of monitoring material demands and emerging trends in the chemical sector, indicating ongoing research and analysis will be necessary [23].

新京报讯（记者田杰雄）4月9日，二十国集团（G20）青年企业家联盟走进昌平暨中国土耳其(北京昌 平)商贸中心启动活动在未来科学城举办。来自土耳其、西班牙、新加坡、APEC等13个国家和组织的 G20青年企业家、中外机构代表齐聚昌平。 记者获悉，昌平区是本次G20青年企业家联盟北京之行的最后一站。昌平的活力与科创文化给G20青年 企业家联盟主席贾玮留下深刻印象。活动当日，中国土耳其商贸中心正式揭牌。贾玮表示，土耳其作为 横跨欧亚的桥梁国家，拥有丰富的资源和广阔的市场；中国作为世界第二大经济体，拥有强大的制造能 力和庞大的消费市场。两者的结合，必将碰撞出耀眼的火花。 记者获悉，未来该中心将架起双向合作桥梁，助力昌平企业开拓"一带一路"市场。助力昌平构筑"技术 共研、市场共拓、资本共融"的国际合作新范式，为北京建设全球数字经济标杆城市注入动能，为世界 青年企业家参与中国式现代化建设打开机遇之窗。 编辑 张树婧 校对 杨利 中国土耳其商贸中心落户昌平。昌平区供图 昌平区委副书记、区长刘晓东在致辞时表示，昌平作为首都平原新城，2024年GDP突破1800亿元、增速 全市第一，正以"两谷一园"创新格局（生命谷、能源谷、沙 ...

Core Viewpoint - Guobang Pharmaceutical (605507) reported strong financial performance for the fiscal year 2024, with significant growth in both revenue and net profit, highlighting its robust position in the pharmaceutical and animal health raw materials market [1][2]. Financial Performance - The company achieved a revenue of 5.891 billion yuan, a year-on-year increase of 10.12%, marking a new high since its listing [1]. - The net profit attributable to shareholders reached 782 million yuan, up 27.61% year-on-year [1]. - The net cash flow from operating activities was 706 million yuan, a substantial increase of 36.7% compared to the previous year [1]. - A cash dividend of 6 yuan per 10 shares was proposed, totaling 335 million yuan, with a payout ratio of 42.86%, the highest in three years [1]. Business Segments - Revenue from pharmaceutical raw materials was 2.477 billion yuan, growing by 11.74%, with a gross margin of 28.36%, an increase of 6.68 percentage points [3]. - Revenue from animal health raw materials reached 1.831 billion yuan, up 11.81%, maintaining a high gross margin of 18.86% [3]. - Key pharmaceutical intermediates generated revenue of 1.13 billion yuan, remaining stable year-on-year, with a gross margin of 33.2% [3]. Product Development - The company has over 38 pharmaceutical raw materials and 16 animal health raw materials approved in China, with production and sales of over 70 chemical drug products [2]. - Major products include azithromycin, clarithromycin, and ciprofloxacin, with the company being one of the largest global suppliers of macrolide and quinolone raw materials [2]. - The company has seen significant sales growth in over 20 products, with 21 products generating over 50 million yuan in revenue and 13 products exceeding 100 million yuan [3]. Global Expansion and R&D - Guobang Pharmaceutical operates a global sales network covering 115 countries, with overseas revenue of 2.664 billion yuan, an increase of 8.27% [5]. - The company invested 215 million yuan in R&D, a 12.88% increase year-on-year, with a strong team of 535 R&D personnel [6]. - A strategic partnership with Zhejiang University aims to enhance collaboration in AI, synthetic biology, and active materials [6]. Sustainability and Safety - The company invested 123 million yuan in safety and environmental protection, implementing various monitoring systems and facilities to enhance its environmental performance [7]. - The company has established a comprehensive environmental management system, contributing to its competitive edge in the market [7].

Core Insights - The National Bio-Manufacturing Industry Innovation Center and Jianfa New Mei Synthetic Biology Industrial Park have established a strategic partnership to create an innovation hub and industrial transformation base in China's synthetic biology sector [1][2]. Group 1: Strategic Collaboration - The National Bio-Manufacturing Industry Innovation Center is the first national-level innovation platform in the bio-manufacturing field in China, aimed at enhancing key common technology collaboration and building an innovative ecosystem [1]. - Jianfa New Mei Synthetic Biology Industrial Park is positioned as a high-end life sciences industrial park focusing on bio-materials and bio-foods, with significant support policies and a complete hardware setup [1][2]. Group 2: Industry Development - The Guangming District has attracted 123 synthetic biology companies with a total valuation of nearly 40 billion yuan, generating an annual output value of over 4 billion yuan in the synthetic biology industry cluster [2]. - A planned investment of 500 million yuan will support industry innovation, alongside the establishment of a 1.5 billion yuan Shenzhen Synthetic Biology Industry Fund to enhance the local synthetic biology ecosystem [2]. Group 3: Future Prospects - The strategic collaboration aims to link technology, capital, and market resources, facilitating the transition of the synthetic biology industry from technological breakthroughs to commercialization [2]. - The partnership is expected to help companies gain a competitive edge in strategic fields such as healthcare and green energy, contributing to the global bio-economy [2].

Core Viewpoint - Beijing Yiqing Holdings is focusing on technological innovation to enhance traditional industries and create new consumption growth points, leveraging artificial intelligence, synthetic biology, and "dual carbon" technologies [1] Group 1: Technological Innovations - Yiqing Holdings showcased six major technological innovations, including an integrated smart factory solution for the textile industry, AI-driven digital printing solutions, and advancements in AI computing efficiency [5] - The "Planet Ring" unmanned beverage station utilizes flexible manufacturing technology to reshape the new retail consumption landscape, with the number of vending machines in China exceeding 1.24 million and an estimated industry transaction volume surpassing 2 trillion [5][6] Group 2: Product Features and Market Adaptation - The "Planet Ring" unmanned beverage station offers four categories of drinks, including freshly ground coffee and brewed tea, and features an intelligent touch interaction system for enhanced user experience [6] - The beverage station is designed to fit various business environments, such as schools, hospitals, and tourist attractions, and includes daily automatic cleaning and standardized inspections for consumer safety [6] Group 3: Collaborations and Partnerships - Yiqing Holdings' subsidiary, Xinghan Internet, partnered with Huawei Technologies to develop joint solutions focusing on network security and AI computing [6] - Yiqing Daily Chemical is collaborating with Tsinghua Yangtze River Delta Research Institute to explore innovative applications of artificial intelligence in the development of active substances for ginseng peptides in skincare [6]

Core Viewpoint - The article highlights the growth and strategic initiatives of Chengzhi Co., focusing on its clean energy and semiconductor display materials sectors, as well as its commitment to sustainable development and shareholder returns [1][12]. Financial Performance - In 2024, Chengzhi Co. achieved a net profit of 231 million yuan, representing a year-on-year increase of 29.98%, with total revenue reaching 11.066 billion yuan [1]. - The company has a consistent dividend policy, proposing a cash dividend of 0.50 yuan per 10 shares, totaling approximately 60.76 million yuan for the current year [2]. Business Strategy - Chengzhi Co. operates under a "one body, two wings" strategy, with the core business focusing on clean energy and extending into high-end chemical materials and life sciences [4][7]. - The clean energy segment is primarily driven by Nanjing Chengzhi, which focuses on clean coal utilization and high-end chemical materials [5]. Market Position and Innovations - The company has adapted to market challenges by adjusting sales strategies and maintaining low inventory levels, effectively capitalizing on high market prices for liquid products [4]. - Chengzhi Co. is actively exploring technological innovations in high-end chemical materials, enhancing product value and market competitiveness [4][6]. Sector Development - The semiconductor display materials sector is experiencing growth due to rising demand in consumer electronics and automotive applications, with the company investing in new technologies to maintain its market position [7]. - In the life sciences sector, Chengzhi Co. is advancing synthetic biology applications, collaborating with academic institutions to enhance production efficiency and product offerings [8][9]. ESG and Corporate Responsibility - The company emphasizes sustainable development and integrates ESG governance into its operations, aiming to balance the interests of shareholders, employees, and society [10]. - Chengzhi Co. engages in social responsibility initiatives, including healthcare support and community service, reflecting its commitment to societal well-being [11].